SG11202009681YA - Ret inhibitor for use in treating cancer having a ret alteration - Google Patents

Ret inhibitor for use in treating cancer having a ret alteration

Info

Publication number
SG11202009681YA
SG11202009681YA SG11202009681YA SG11202009681YA SG11202009681YA SG 11202009681Y A SG11202009681Y A SG 11202009681YA SG 11202009681Y A SG11202009681Y A SG 11202009681YA SG 11202009681Y A SG11202009681Y A SG 11202009681YA SG 11202009681Y A SG11202009681Y A SG 11202009681YA
Authority
SG
Singapore
Prior art keywords
ret
treating cancer
alteration
inhibitor
ret inhibitor
Prior art date
Application number
SG11202009681YA
Inventor
Raab Erica Evans
Beni B Wolf
Original Assignee
Blueprint Medicines Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Blueprint Medicines Corp filed Critical Blueprint Medicines Corp
Publication of SG11202009681YA publication Critical patent/SG11202009681YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
SG11202009681YA 2018-04-03 2019-04-03 Ret inhibitor for use in treating cancer having a ret alteration SG11202009681YA (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862652284P 2018-04-03 2018-04-03
US201862656297P 2018-04-11 2018-04-11
US201862657605P 2018-04-13 2018-04-13
US201862741683P 2018-10-05 2018-10-05
PCT/US2019/025655 WO2019195471A1 (en) 2018-04-03 2019-04-03 Ret inhibitor for use in treating cancer having a ret alteration

Publications (1)

Publication Number Publication Date
SG11202009681YA true SG11202009681YA (en) 2020-10-29

Family

ID=66223846

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202009681YA SG11202009681YA (en) 2018-04-03 2019-04-03 Ret inhibitor for use in treating cancer having a ret alteration

Country Status (21)

Country Link
US (4) US20210100795A1 (en)
EP (2) EP3773589B1 (en)
JP (3) JP7422084B2 (en)
KR (1) KR20200139749A (en)
AU (1) AU2019247766A1 (en)
BR (1) BR112020020273A2 (en)
CA (1) CA3096043A1 (en)
CL (1) CL2020002544A1 (en)
CR (1) CR20200522A (en)
DK (1) DK3773589T3 (en)
FI (1) FI3773589T3 (en)
IL (1) IL277629A (en)
LT (1) LT3773589T (en)
MX (1) MX2020010417A (en)
PE (1) PE20210096A1 (en)
PL (1) PL3773589T3 (en)
PT (1) PT3773589T (en)
RS (1) RS65127B1 (en)
SG (1) SG11202009681YA (en)
SI (1) SI3773589T1 (en)
WO (1) WO2019195471A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016127074A1 (en) 2015-02-06 2016-08-11 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors
KR20180073689A (en) 2015-11-02 2018-07-02 블루프린트 메디신즈 코포레이션 Inhibitors of RET
CR20200522A (en) 2018-04-03 2021-02-17 Blueprint Medicines Corp Ret inhibitor for use in treating cancer having a ret alteration
US11666570B2 (en) * 2019-07-11 2023-06-06 The Board Of Trustees Of The Leland Stanford Junior University Diagnosis and regulation of epidermal differentiation and cancer cell activity
US11946935B2 (en) * 2020-08-25 2024-04-02 Regents Of The University Of Minnesota Circulating tumor markers for meningiomas

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1429222A (en) 2000-02-17 2003-07-09 安姆根有限公司 Kinase inhibitors
US20060116381A1 (en) 2002-07-24 2006-06-01 Fagin James A 4-4(methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-ben-zamide for treating mutated-ret kinase associated diseases
PL1696920T3 (en) 2003-12-19 2015-03-31 Plexxikon Inc Compounds and methods for development of ret modulators
US8227455B2 (en) 2005-04-18 2012-07-24 Rigel Pharmaceuticals, Inc. Methods of treating cell proliferative disorders
UA92746C2 (en) 2005-05-09 2010-12-10 Акилайон Фармасьютикалз, Инк. Thiazole compounds and methods of use
WO2006128042A2 (en) 2005-05-26 2006-11-30 The Johns Hopkins University Methods of identifying mutations in nucleic acid
WO2007023382A2 (en) 2005-08-25 2007-03-01 Pfizer Inc. Pyrimidine amino pyrazole compounds, potent kinase inhibitors
WO2007087245A2 (en) 2006-01-24 2007-08-02 Merck & Co., Inc. Ret tyrosine kinase inhibition
RU2448708C3 (en) 2006-05-18 2017-09-28 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. ANTI-TUMOR MEANS AGAINST THYROID CANCER CANCER
US20090048214A1 (en) 2006-11-15 2009-02-19 Rigel Pharmaceuticals, Inc Methods for Treating Renal Tumors Using 2, 4-Pyrimidinediamine Drug and Prodrug Compounds
US20090012045A1 (en) 2007-06-26 2009-01-08 Rigel Pharmaceuticals, Inc. Methods of Treating Cell Proliferative Disorders
JP2010533158A (en) 2007-07-09 2010-10-21 アストラゼネカ アクチボラグ Compounds-945
KR101552742B1 (en) 2007-07-19 2015-09-11 머크 샤프 앤드 돔 코포레이션 Heterocyclic Amide Compounds as Protein Kinase Inhibitors
WO2009100536A1 (en) 2008-02-15 2009-08-20 Methylgene Inc. Inhibitors of kinase activity with 1,2-di-cyclyl substituted alkyne structures
EP2313091A4 (en) 2008-07-14 2012-04-04 Univ Kingston Pharmaceutical compositions comprising ret inhibitors and methods for the treatment of cancer
US8367690B2 (en) 2009-03-24 2013-02-05 Vertex Pharmaceuticals Inc. Aminopyridine derivatives having aurora a selective inhibitory action
KR20120034726A (en) 2009-06-08 2012-04-12 아브락시스 바이오사이언스, 엘엘씨 Triazine derivatives and their therapeutical applications
KR20120026612A (en) 2009-06-09 2012-03-19 아브락시스 바이오사이언스, 엘엘씨 Benzyl substituted triazine derivatives and their therapeutical applications
AU2010313152A1 (en) 2009-10-30 2012-04-19 Ariad Pharmaceuticals, Inc. Methods and compositions for treating cancer
US8629132B2 (en) 2009-11-13 2014-01-14 Genosco Kinase inhibitors
CA2848369A1 (en) 2011-08-04 2013-02-07 National Cancer Center Fusion gene of kif5b gene and ret gene, and method for determining effectiveness of cancer treatment targeting fusion gene
ES2704126T3 (en) 2011-08-23 2019-03-14 Found Medicine Inc KIF5B-RET fusion molecules and their uses
EP2751112B1 (en) 2011-09-02 2019-10-09 The Regents of The University of California Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
US20130096136A1 (en) 2011-09-30 2013-04-18 Methylgene Inc. Inhibitors of Protein Tyrosine Kinase Activity
US10023855B2 (en) 2011-10-31 2018-07-17 Macrogen, Inc. Fusion protein comprising C-terminal domain of RET protein and use thereof as a diagnosing marker
US8841450B2 (en) 2011-11-09 2014-09-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
WO2013133367A1 (en) 2012-03-09 2013-09-12 カルナバイオサイエンス株式会社 Novel triazine derivative
JP2015109806A (en) 2012-03-22 2015-06-18 アステラス製薬株式会社 Method for detecting new ret fused body
IN2014MN02056A (en) 2012-04-25 2015-08-21 Raqualia Pharma Inc
EP2849751A1 (en) 2012-05-10 2015-03-25 Synta Pharmaceuticals Corp. Treating cancer with hsp90 inhibitory compounds
PT2872491T (en) 2012-07-11 2021-08-05 Blueprint Medicines Corp Inhibitors of the fibroblast growth factor receptor
EP2878672A4 (en) 2012-07-26 2016-02-17 Nat Cancer Ct Fusion gene of cep55 gene and ret gene
CN114129566A (en) 2012-09-07 2022-03-04 埃克塞里艾克西斯公司 Inhibitors of MET, VEGFR and RET for the treatment of lung adenocarcinoma
SI2902029T1 (en) 2012-09-25 2018-11-30 Chugai Seiyaku Kabushiki Kaisha Ret inhibitor
CN108047219A (en) 2012-11-07 2018-05-18 内尔维阿诺医学科学有限公司 Substituted pyrimidine radicals and Pyridylpyrrole and pyridinone, its preparation method and its purposes as kinase inhibitor
TWI629266B (en) 2012-12-28 2018-07-11 藍印藥品公司 Inhibitors of the fibroblast growth factor receptor
SG11201506445PA (en) 2013-02-25 2015-09-29 Bristol Myers Squibb Co C-3 alkyl and alkenyl modified betulinic acid derivatives useful in the treatment of hiv
EP2970231A1 (en) 2013-03-15 2016-01-20 Blueprint Medicines Corporation Piperazine derivatives and their use as kit modulators
PL2970191T3 (en) 2013-03-15 2017-07-31 Glaxosmithkline Intellectual Property Development Limited Pyridine derivatives as rearranged during transfection (ret) kinase inhibitors
IN2013MU00848A (en) 2013-03-19 2015-05-01 Glenmark Generics Ltd
WO2015006875A1 (en) 2013-07-18 2015-01-22 Methylgene Inc. Process for the preparation of substituted pyrimidines
TW201542825A (en) 2013-08-20 2015-11-16 Nat Cancer Ct Novel fused gene identified in lung cancer
HUE039687T2 (en) 2013-10-17 2019-01-28 Blueprint Medicines Corp Compositions useful for treating disorders related to kit
WO2015058129A1 (en) 2013-10-17 2015-04-23 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
SI3395814T1 (en) 2013-10-25 2022-10-28 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
GB201321146D0 (en) 2013-11-29 2014-01-15 Cancer Rec Tech Ltd Quinazoline compounds
US9695165B2 (en) 2014-01-15 2017-07-04 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
US9688680B2 (en) 2014-08-04 2017-06-27 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
KR20170046180A (en) 2014-09-10 2017-04-28 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Novel compounds as rearranged during transfection (ret) inhibitors
MY181913A (en) 2014-09-10 2021-01-14 Glaxosmithkline Ip Dev Ltd Pyridone derivatives as rearranged during transfection (ret) kinase inhibitors
JP6421241B2 (en) 2014-11-14 2018-11-07 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ 6-amino-7-bicyclo-7-deaza-purine derivatives as protein kinase inhibitors
WO2016127074A1 (en) 2015-02-06 2016-08-11 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors
CN104844567B (en) 2015-04-23 2017-03-29 暨南大学 A kind of synthetic method of intermediate 1 (3 chlorine, 2 pyridine radicals) 3 bromine 1H, 5 pyrazole carboxylic acids
CN108349969B (en) 2015-07-16 2022-05-10 阵列生物制药公司 Substituted pyrazolo [1,5-a ] pyridine compounds as RET kinase inhibitors
CN108026102A (en) 2015-07-24 2018-05-11 蓝印药品公司 Available for treatment and the compound of the relevant illnesss of KIT and PDGFR
WO2017035354A1 (en) 2015-08-26 2017-03-02 Blueprint Medicines Corporation Compounds and compositions useful for treating disorders related to ntrk
CN105255927B (en) 2015-09-30 2018-07-27 温州医科大学附属第一医院 A kind of KIAA1217-RET fusions
KR20180073689A (en) 2015-11-02 2018-07-02 블루프린트 메디신즈 코포레이션 Inhibitors of RET
MX2018005545A (en) 2015-11-02 2019-02-20 Janssen Pharmaceutica Nv Anti-il1rap antibodies, bispecific antigen binding molecules that bind il1rap and cd3, and uses thereof.
EA201891106A1 (en) 2015-11-02 2018-12-28 Файв Прайм Терапьютикс, Инк. POLYPEPTIDES OF CD80 OUT-CELL DOMAIN AND THEIR APPLICATION IN CANCER TREATMENT
AR106756A1 (en) 2015-11-19 2018-02-14 Blueprint Medicines Corp USEFUL COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF NTRK-RELATED DISORDERS
CA3007644A1 (en) 2015-12-11 2017-06-15 Regeneron Pharmaceuticals, Inc. Methods for reducing or preventing growth of tumors resistant to egfr and/or erbb3 blockade
WO2017145050A1 (en) 2016-02-23 2017-08-31 Glaxosmithkline Intellectual Property Development Limited Pyridylpyridone derivative useful as a ret kinase inhibitor in the treatment of ibs and cancer
TW201738228A (en) 2016-03-17 2017-11-01 藍圖醫藥公司 Inhibitors of RET
AU2017241837B2 (en) 2016-04-01 2021-07-22 Signal Pharmaceuticals, Llc Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
SG11201808878UA (en) 2016-04-15 2018-11-29 Cancer Research Tech Ltd Heterocyclic compounds as ret kinase inhibitors
AU2017250302B2 (en) 2016-04-15 2021-01-21 Blueprint Medicines Corporation Inhibitors of activin receptor-like kinase
HUE060082T2 (en) 2016-04-15 2023-01-28 Cancer Research Tech Ltd Heterocyclic compounds as ret kinase inhibitors
WO2018017983A1 (en) 2016-07-22 2018-01-25 Blueprint Medicines Corporation Compounds useful for treating disorders related to ret
WO2018022761A1 (en) 2016-07-27 2018-02-01 Blueprint Medicines Corporation Substituted cyclopentane-amides for treating disorders related to ret
CN110022900A (en) 2016-09-08 2019-07-16 蓝图药品公司 The combination of fibroblast growth factor receptor 4 inhibitor and cell cycle protein dependent kinase inhibitor
JP2018052878A (en) 2016-09-29 2018-04-05 第一三共株式会社 Pyridine compound
CN106749231B (en) 2016-10-09 2019-03-01 南京纳丁菲医药科技有限公司 Naphthyridine compounds and pharmaceutical composition and their application
TWI704148B (en) * 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
JOP20190077A1 (en) 2016-10-10 2019-04-09 Array Biopharma Inc Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
US10799503B2 (en) 2016-12-01 2020-10-13 Ignyta, Inc. Methods for the treatment of cancer
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
JP6888101B2 (en) 2017-01-18 2021-06-16 アレイ バイオファーマ インコーポレイテッド Substituted pyrazolo [1,5-a] pyrazine compounds as RET kinase inhibitors
WO2018183712A1 (en) 2017-03-31 2018-10-04 Blueprint Medicines Corporation Pyrrolo[1,2-b]pyridazine compounds and compositions useful for treating disorders related to kit and pdgfr
GB201705971D0 (en) 2017-04-13 2017-05-31 Cancer Res Tech Ltd Inhibitor compounds
CN110891573A (en) * 2017-05-15 2020-03-17 缆图药品公司 Combinations of RET inhibitors and MTORC1 inhibitors and their use for treating cancers mediated by aberrant RET activity
WO2018237134A1 (en) 2017-06-23 2018-12-27 San Diego State University Research Foundation Atropisomerism for enhanced kinase inhibitor selectivity
CN109180677A (en) 2017-06-30 2019-01-11 厦门大学 Substituted aryl ethers compounds, preparation method, Pharmaceutical composition and its application
WO2019008172A1 (en) 2017-07-07 2019-01-10 Nipd Genetics Public Company Limited Target-enriched multiplexed parallel analysis for assessment of tumor biomarkers
CN107980784B (en) 2017-12-13 2020-05-26 中国农业大学 Application of 5-aminopyrazole compounds in regulating plant growth
PL3728271T3 (en) 2017-12-19 2023-01-23 Turning Point Therapeutics, Inc. Macrocyclic compounds for treating diseases
WO2019143994A1 (en) 2018-01-18 2019-07-25 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
US11524963B2 (en) 2018-01-18 2022-12-13 Array Biopharma Inc. Substituted pyrazolo[3,4-d]pyrimidines as RET kinase inhibitors
TWI802635B (en) 2018-01-18 2023-05-21 美商亞雷生物製藥股份有限公司 Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
CN108341782A (en) 2018-03-30 2018-07-31 南京哈柏医药科技有限公司 The synthesis technology of 3- amino-5-methylpyrazoles
CR20200522A (en) 2018-04-03 2021-02-17 Blueprint Medicines Corp Ret inhibitor for use in treating cancer having a ret alteration
US20210308134A1 (en) 2018-08-10 2021-10-07 Blueprint Medicines Corporation Treatment of egfr-mutant cancer
CN111362923A (en) 2020-03-25 2020-07-03 魏威 Method for preparing RET inhibitor pracetib, intermediate of pracetib and preparation method of pracetib
CN111440151A (en) 2020-03-25 2020-07-24 魏威 Method for preparing antitumor drug prasutinib
MX2022014858A (en) 2020-05-29 2023-02-23 Blueprint Medicines Corp Solid forms of pralsetinib.
AU2021281283A1 (en) 2020-05-29 2022-12-15 Blueprint Medicines Corporation Pralsetinib pharmaceutical compositions
AU2021390534A1 (en) 2020-12-04 2023-06-22 Blueprint Medicines Corporation Method of preparing pralsetinib

Also Published As

Publication number Publication date
IL277629A (en) 2020-11-30
RS65127B1 (en) 2024-02-29
EP4353317A2 (en) 2024-04-17
LT3773589T (en) 2024-02-12
US20210100799A1 (en) 2021-04-08
EP3773589B1 (en) 2023-11-01
CA3096043A1 (en) 2019-10-10
BR112020020273A2 (en) 2021-04-06
DK3773589T3 (en) 2024-01-29
JP2022022391A (en) 2022-02-03
JP2023165937A (en) 2023-11-17
EP3773589A1 (en) 2021-02-17
RU2020135917A (en) 2022-05-04
PT3773589T (en) 2024-02-06
CR20200522A (en) 2021-02-17
FI3773589T3 (en) 2024-02-01
MX2020010417A (en) 2021-01-08
JP7422084B2 (en) 2024-01-25
CL2020002544A1 (en) 2021-06-11
PL3773589T3 (en) 2024-04-02
SI3773589T1 (en) 2024-03-29
US11273160B2 (en) 2022-03-15
US20210085680A1 (en) 2021-03-25
KR20200139749A (en) 2020-12-14
JP2021520349A (en) 2021-08-19
US20220175773A1 (en) 2022-06-09
US11872192B2 (en) 2024-01-16
US20210100795A1 (en) 2021-04-08
WO2019195471A1 (en) 2019-10-10
AU2019247766A1 (en) 2020-10-15
PE20210096A1 (en) 2021-01-12

Similar Documents

Publication Publication Date Title
IL277783A (en) Shp2 inhibitor compositions, methods for treating cancer and methods for identifying a subject with shp2 mutations
IL277629A (en) Ret inhibitor for use in treating cancer having a ret alteration
IL282663A (en) Bt1718 for use in treating cancer
IL255189B2 (en) A combination of rad1901 and a cdk4/6 inhibitor for use in treating cancer
IL284199A (en) Csf1r inhibitors for use in treating cancer
PL3371165T3 (en) A btk inhibitor for use in treating cancer
IL259479B (en) Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor
SI3534885T1 (en) Farnesyltransferase inhibitors for use in treating cancer
GB201820660D0 (en) Cancer treatments
SG11202010528XA (en) Combinations for treating cancer
IL284856A (en) A dbait molecule in combination with kinase inhibitor for the treatment of cancer
EP3966208A4 (en) Compounds and methods for treating cancer
ZA202007955B (en) Ccr5 inhibitor for use in treating cancer
IL285538A (en) Combination therapies for use in treating cancer
IL283687A (en) Usp19 inhibitors for use in therapy
GB201611365D0 (en) A composition for use in treating rotavirus infection
PT3813832T (en) Compounds for use in preventing or treating cancer
EP4019634A4 (en) Compounds and methods for treating cancer
GB201807415D0 (en) Cancer treatments
GB201802264D0 (en) Cancer treatments